SAR131675: Selective VEGFR-3 Inhibitor for Dissecting Lymphangiogenesis and Tumor Microenvironment

Introduction

The vascular endothelial growth factor receptor-3 (VEGFR-3) signaling pathway is central to the regulation of lymphangiogenesis, angiogenesis, and the orchestration of the tumor microenvironment. Disruption of this pathway is increasingly recognized as a promising avenue for modulating tumor growth, metastasis, and tissue fibrosis. SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor, has emerged as a powerful chemical probe for dissecting these complex biological processes, thanks to its high specificity and nanomolar potency. While previous literature has highlighted SAR131675's efficacy in targeting VEGFR signaling in cancer and fibrosis models, this article delivers a fresh perspective by integrating recent mechanistic advances in the regulation of the lymphatic-immune interface and tumor microenvironment, particularly focusing on macrophage phenotypic switching and stromal-immune cross-talk.

Mechanism of Action: SAR131675 as a Selective ATP-Competitive VEGFR-3 Inhibitor

SAR131675 (B2301) is a small-molecule inhibitor that binds the ATP-binding site of VEGFR-3 with remarkable affinity (IC₅₀ = 23 nM, K_i = 12 nM), effectively blocking VEGFR-3 autophosphorylation in cellular contexts (IC₅₀ 30–50 nM in HEK cells). Its selectivity profile is exceptional: SAR131675 demonstrates minimal inhibition of VEGFR-1 (IC₅₀ > 3 μM) and VEGFR-2 (IC₅₀ 235 nM) and exhibits negligible activity against a diverse panel of 65 kinases, 107 non-kinase enzymes/receptors, and 21 ion channels. This high degree of specificity makes SAR131675 a robust VEGFR signaling pathway inhibitor with minimal off-target effects—a critical feature for mechanistic studies in cancer biology and fibrosis.

Functionally, SAR131675 potently inhibits lymphatic endothelial cell (LEC) survival induced by VEGFC (IC₅₀ 14 nM) and VEGFD (IC₅₀ 17 nM), as well as migration of human lung microvascular endothelial cells (HLMVEC) driven by both VEGFA (IC₅₀ 100 nM) and VEGFC (<30 nM). These activities establish SAR131675 as both an anti-lymphangiogenic agent and anti-angiogenic compound. In vivo, it suppresses pathologic lymphangiogenesis and angiogenesis stimulated by FGF2, and demonstrates tumor volume reduction in preclinical models such as the 4T1 mammary carcinoma mouse model, making it a valuable antitumor agent in preclinical cancer models and a tool for inhibitor for tumor metastasis research.

Beyond Endothelial Cells: SAR131675 in the Modulation of the Tumor Microenvironment

VEGFR-3 Signaling and the Tumor-Immune Axis

While the primary literature often centers on SAR131675’s efficacy as a VEGFR-3 autophosphorylation inhibitor and its ability to block lymphangiogenesis, emerging research has illuminated its impact on the tumor immune microenvironment. Notably, the reference study by Jingya Li et al. (Phytomedicine, 2026) demonstrates that the VEGFC/VEGFR-3 signaling axis not only drives lymphatic vessel growth but also modulates macrophage infiltration and phenotypic switching within fibrotic and tumorigenic tissues. SAR131675, by selectively inhibiting VEGFR-3, disrupts this axis, resulting in reduced Ly6C^high monocyte infiltration and a shift toward the Ly6C^low reparative macrophage phenotype in liver fibrosis models. This phenotypic modulation is crucial, as tumor-associated macrophages (TAMs) heavily influence tumor progression, immune evasion, and response to therapy.

Dissecting the VEGFC–Macrophage Regulatory Axis

The referenced study provides a mechanistic framework: hepatocyte-derived VEGFC promotes macrophage migration via VEGFR-3 and the CCL2/CCR2 chemokine axis, while simultaneously inhibiting phenotypic transition through IL-10 and CX3CR1 regulation. SAR131675, by blocking VEGFR-3 signaling, disrupts both the recruitment of pro-inflammatory monocytes and the maintenance of a pro-fibrotic macrophage population. This dual effect underscores SAR131675’s unique value as a research compound for unraveling the interplay between lymphatic signaling and immune cell dynamics within the tumor microenvironment, extending its utility far beyond traditional endothelial biology.

Comparative Analysis: SAR131675 Versus Alternative VEGFR Inhibitors

Many existing reviews, such as "SAR131675 and the Future of VEGFR-3 Pathway Inhibition", provide a broad mechanistic and translational overview of SAR131675 and its role in dissecting the VEGFR signaling pathway. While these works emphasize its selectivity and translational potential, this article goes further by detailing the specific impact of SAR131675 on the tumor-immune interface and macrophage functional states—a niche not deeply explored in prior analyses.

Compared to other VEGFR inhibitors, SAR131675 stands out for its nanomolar potency and extremely low off-target activity. Many pan-VEGFR inhibitors affect VEGFR-1 and VEGFR-2, confounding the analysis of VEGFR-3-specific biology. SAR131675’s unique selectivity enables researchers to attribute observed biological effects specifically to VEGFR-3 inhibition, whether in the context of lymphatic endothelial cell survival, angiogenesis pathway regulation, or immune cell infiltration.

Other articles, such as "SAR131675: A Selective VEGFR-3 Inhibitor for Tumor and Fibrosis Research", focus on SAR131675's use for pathway dissection in cancer and fibrosis. In contrast, this article uniquely emphasizes advanced concepts of stromal-immune crosstalk, integrating recent evidence on macrophage regulation and its implications for both the tumor microenvironment and tissue remodeling.

Advanced Applications: SAR131675 in Cancer Research and Beyond

VEGFR-3 Inhibition in Tumor Growth and Metastasis

SAR131675 has demonstrated robust antitumor efficacy in preclinical models by significantly reducing tumor volume and inhibiting both lymphangiogenesis and angiogenesis. These properties make it an invaluable tool for cancer research, especially in studies dissecting the tumor angiogenesis pathway, metastasis, and lymphatic remodeling. The compound’s cell permeability and in vivo activity enable researchers to model both cell-autonomous and systemic effects of VEGFR-3 inhibition in tumor biology.

Regulating the Lymphangiogenesis Pathway in Fibrosis and Inflammation

As highlighted in the recent reference study, SAR131675’s inhibition of the VEGFC–VEGFR-3 axis ameliorates hepatic fibrosis and reduces liver inflammation in high-fat diet-induced NASH models. This is achieved by lowering VEGFC levels, reducing Ly6C^high monocyte/macrophage infiltration, and promoting reparative macrophage phenotypes. Moreover, these findings implicate VEGFR-3 inhibition as a strategy for modulating immune responses and tissue repair mechanisms in metabolic and inflammatory diseases, not just in oncology.

Precision Dissection of VEGFR Signaling Pathways

Other content, such as "Precision Targeting of VEGFR-3: Strategic Guidance for Translational Research", provides a roadmap for using SAR131675 to dissect VEGFR signaling in cancer and fibrosis. This article builds on such guidance by integrating new mechanistic insights into macrophage regulation, offering researchers a more holistic understanding of the VEGFR-3 axis as it relates to immune modulation, lymphatic remodeling, and the tumor microenvironment.

For further technical and application-focused perspectives, readers may consult "SAR131675: Precision VEGFR-3 Inhibitor for Lymphangiogenesis and Angiogenesis Research", which focuses on pathway-targeted experimental design. In contrast, the current article provides an integrative analysis of how VEGFR-3 selective kinase inhibition can be leveraged to unravel complex cellular crosstalk in disease models.

Product Considerations and Limitations

SAR131675, supplied as a solid by APExBIO, is cell permeable and is recommended for storage at -20°C. The compound is insoluble in DMSO, ethanol, and water, and freshly prepared solutions are advised for experimental consistency. Importantly, despite its promising preclinical profile, SAR131675's clinical development was discontinued due to adverse metabolic effects observed in animal studies, underscoring the necessity for careful interpretation of in vivo results and further chemical refinement for translational applications. This limitation does not diminish its value as a preclinical research tool for the selective interrogation of the VEGFR-3/VEGFC axis in cancer biology and tissue fibrosis.

Conclusion and Future Outlook

SAR131675 has established itself as a gold standard VEGFR-3 selective kinase inhibitor for advanced cancer biology research and translational studies targeting lymphangiogenesis and the tumor microenvironment. By leveraging its unparalleled selectivity and insight from recent mechanistic studies, researchers can elucidate the multifaceted roles of the VEGFR signaling pathway—including immune modulation and stromal-immune crosstalk—in both neoplastic and fibrotic diseases. While its clinical development has been halted due to metabolic liabilities, SAR131675 remains an indispensable tool for preclinical studies and hypothesis-driven research into the tumor-immune-lymphatic interface.

For detailed product specifications and ordering information, visit the official APExBIO SAR131675 product page.

Citation: Mechanistic insights in this article were grounded in the comprehensive study by Jingya Li et al., Phytomedicine, 2026 (link), which elucidates the role of VEGFC/VEGFR-3 signaling in hepatic fibrosis, macrophage regulation, and therapeutic intervention using SAR131675.